Literature DB >> 17261619

Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.

Anita Reinhardt1, Thilo Köhler, Paul Wood, Peter Rohner, Jean-Luc Dumas, Bara Ricou, Christian van Delden.   

Abstract

Intubated patients frequently become colonized by Pseudomonas aeruginosa, which is subsequently responsible for ventilator-associated pneumonia. This pathogen readily acquires resistance against available antimicrobials. Depending on the resistance mechanism selected for, resistance might either be lost or persist after removal of the selective pressure. We investigated the rapidity of selection, as well as the persistence, of antimicrobial resistance and determined the underlying mechanisms. We selected 109 prospectively collected P. aeruginosa tracheal isolates from two patients based on their prolonged intubation and colonization periods, during which they had received carbapenem, fluoroquinolone (FQ), or combined beta-lactam-aminoglycoside therapies. We determined antimicrobial resistance phenotypes by susceptibility testing and used quantitative real-time PCR to measure the expression of resistance determinants. Within 10 days after the initiation of therapy, all treatment regimens selected resistant isolates. Resistance to beta-lactam and FQ was correlated with ampC and mexC gene expression levels, respectively, whereas imipenem resistance was attributable to decreased oprD expression. Combined beta-lactam-aminoglycoside resistance was associated with the appearance of small-colony variants. Imipenem and FQ resistance persisted for prolonged times once the selecting antimicrobial treatment had been discontinued. In contrast, resistance to beta-lactams disappeared rapidly after removal of the selective pressure, to reappear promptly upon renewed exposure. Our results suggest that resistant P. aeruginosa is selected in less than 10 days independently of the antimicrobial class. Different resistance mechanisms lead to the loss or persistence of resistance after the removal of the selecting agent. Even if resistant isolates are not evident upon culture, they may persist in the lung and can be rapidly reselected.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261619      PMCID: PMC1855521          DOI: 10.1128/AAC.01278-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  beta-Lactamases: quantity and resistance.

Authors:  David M. Livermore
Journal:  Clin Microbiol Infect       Date:  1997-02       Impact factor: 8.067

Review 2.  Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms.

Authors:  Michael S Niederman
Journal:  Clin Infect Dis       Date:  2006-01-15       Impact factor: 9.079

3.  Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  S Jalal; B Wretlind
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

4.  Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection?

Authors:  J Rello; D Mariscal; F March; P Jubert; F Sanchez; J Valles; P Coll
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

5.  Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats.

Authors:  O F Join-Lambert; M Michéa-Hamzehpour; T Köhler; F Chau; F Faurisson; S Dautrey; C Vissuzaine; C Carbon; J Pechère
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Patrice Nordmann; Farid El Garch; Ludovic Cabanne; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 7.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

8.  Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa.

Authors:  H Yoneyama; T Nakae
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

9.  Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance.

Authors:  Daniel J Wolter; Nancy D Hanson; Philip D Lister
Journal:  FEMS Microbiol Lett       Date:  2004-07-01       Impact factor: 2.742

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  24 in total

1.  Bacterial recombination promotes the evolution of multi-drug-resistance in functionally diverse populations.

Authors:  Gabriel G Perron; Alexander E G Lee; Yun Wang; Wei E Huang; Timothy G Barraclough
Journal:  Proc Biol Sci       Date:  2011-11-02       Impact factor: 5.349

2.  Multidrug therapy and evolution of antibiotic resistance: when order matters.

Authors:  Gabriel G Perron; Sergey Kryazhimskiy; Daniel P Rice; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-22       Impact factor: 4.792

3.  The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.

Authors:  Hsun-Cheng Su; Kevin Ramkissoon; Janet Doolittle; Martha Clark; Jainab Khatun; Ashley Secrest; Matthew C Wolfgang; Morgan C Giddings
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

Review 4.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  Evaluation of the βLACTA test, a novel commercial chromogenic test for rapid detection of ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates.

Authors:  Terry Laurent; Te-Din Huang; Pierre Bogaerts; Youri Glupczynski
Journal:  J Clin Microbiol       Date:  2013-04-10       Impact factor: 5.948

6.  Comparative genome analysis of ciprofloxacin-resistant Pseudomonas aeruginosa reveals genes within newly identified high variability regions associated with drug resistance development.

Authors:  Hsun-Cheng Su; Jainab Khatun; Dona M Kanavy; Morgan C Giddings
Journal:  Microb Drug Resist       Date:  2013-06-29       Impact factor: 3.431

7.  Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing.

Authors:  Inmaculada Martínez-Ramos; Xavier Mulet; Bartolomé Moyá; Mariette Barbier; Antonio Oliver; Sebastián Albertí
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

8.  Risk of drug resistance in repeat gram-negative infections among patients with multiple hospitalizations.

Authors:  Mansi Agarwal; Elaine L Larson
Journal:  J Crit Care       Date:  2017-09-18       Impact factor: 3.425

9.  YfiBNR mediates cyclic di-GMP dependent small colony variant formation and persistence in Pseudomonas aeruginosa.

Authors:  Jacob G Malone; Tina Jaeger; Christian Spangler; Daniel Ritz; Anne Spang; Cécile Arrieumerlou; Volkhard Kaever; Regine Landmann; Urs Jenal
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

10.  A novel signaling network essential for regulating Pseudomonas aeruginosa biofilm development.

Authors:  Olga E Petrova; Karin Sauer
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.